IL116109A - תרכובות ביניים להכנת sic- נוקליאוסידים ואנלוגים של נוקליאוסידבעלי פעילות אופטית - Google Patents

תרכובות ביניים להכנת sic- נוקליאוסידים ואנלוגים של נוקליאוסידבעלי פעילות אופטית

Info

Publication number
IL116109A
IL116109A IL11610992A IL11610992A IL116109A IL 116109 A IL116109 A IL 116109A IL 11610992 A IL11610992 A IL 11610992A IL 11610992 A IL11610992 A IL 11610992A IL 116109 A IL116109 A IL 116109A
Authority
IL
Israel
Prior art keywords
formula
cis
carbonyl
derivative
choh
Prior art date
Application number
IL11610992A
Other languages
English (en)
Original Assignee
Iaf Biochem Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24825144&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL116109(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Iaf Biochem Int filed Critical Iaf Biochem Int
Publication of IL116109A publication Critical patent/IL116109A/he

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/24Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/32Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/32Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D317/34Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D327/00Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D327/02Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms one oxygen atom and one sulfur atom
    • C07D327/04Five-membered rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D339/00Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
    • C07D339/02Five-membered rings
    • C07D339/06Five-membered rings having the hetero atoms in positions 1 and 3, e.g. cyclic dithiocarbonates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D411/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/04Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06Pyrimidine radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Catalysts (AREA)
  • Furan Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Vehicle Step Arrangements And Article Storage (AREA)
IL11610992A 1991-05-21 1992-05-20 תרכובות ביניים להכנת sic- נוקליאוסידים ואנלוגים של נוקליאוסידבעלי פעילות אופטית IL116109A (he)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70337991A 1991-05-21 1991-05-21
IL10193192A IL101931A (he) 1991-05-21 1992-05-20 תהליכים לסינתיזה דיאסטיריאוסלקטיביתשל sic- נוקליאוסידים ואנלוגים של נוקליאוסיד

Publications (1)

Publication Number Publication Date
IL116109A true IL116109A (he) 1998-12-27

Family

ID=24825144

Family Applications (6)

Application Number Title Priority Date Filing Date
IL11610992A IL116109A (he) 1991-05-21 1992-05-20 תרכובות ביניים להכנת sic- נוקליאוסידים ואנלוגים של נוקליאוסידבעלי פעילות אופטית
IL10193192A IL101931A (he) 1991-05-21 1992-05-20 תהליכים לסינתיזה דיאסטיריאוסלקטיביתשל sic- נוקליאוסידים ואנלוגים של נוקליאוסיד
IL116176A IL116176A (he) 1991-05-21 1992-05-20 תרכובות אמצעיות עבור סינתיזה דיאסטיריוסלקטיבית של אנאלוגים של sic - נוקלאוסיד
IL101932A IL101932A (en) 1991-05-21 1992-05-20 Processes for the diastereoselective synthesis of cis-nucleoside analogues
IL11610995A IL116109A0 (en) 1991-05-21 1995-11-23 Intermediate compounds for the diastereoselective synthesis of cis-nucleosides
IL11617695A IL116176A0 (en) 1991-05-21 1995-11-28 Intermediate compounds for the diastereoselective synthesis of cis-nucleoside analogues

Family Applications After (5)

Application Number Title Priority Date Filing Date
IL10193192A IL101931A (he) 1991-05-21 1992-05-20 תהליכים לסינתיזה דיאסטיריאוסלקטיביתשל sic- נוקליאוסידים ואנלוגים של נוקליאוסיד
IL116176A IL116176A (he) 1991-05-21 1992-05-20 תרכובות אמצעיות עבור סינתיזה דיאסטיריוסלקטיבית של אנאלוגים של sic - נוקלאוסיד
IL101932A IL101932A (en) 1991-05-21 1992-05-20 Processes for the diastereoselective synthesis of cis-nucleoside analogues
IL11610995A IL116109A0 (en) 1991-05-21 1995-11-23 Intermediate compounds for the diastereoselective synthesis of cis-nucleosides
IL11617695A IL116176A0 (en) 1991-05-21 1995-11-28 Intermediate compounds for the diastereoselective synthesis of cis-nucleoside analogues

Country Status (34)

Country Link
US (5) US5756706A (he)
EP (2) EP0515157B1 (he)
JP (3) JP3330972B2 (he)
KR (3) KR0160144B1 (he)
CN (6) CN1035555C (he)
AT (2) ATE133958T1 (he)
AU (4) AU655973B2 (he)
BG (2) BG61696B1 (he)
CA (2) CA2069063C (he)
CZ (3) CZ222496A3 (he)
DE (2) DE69221936T2 (he)
DK (2) DK0515156T3 (he)
EE (1) EE03044B1 (he)
ES (2) ES2104832T3 (he)
FI (3) FI109025B (he)
GR (2) GR3018941T3 (he)
GT (1) GT199800047A (he)
HK (2) HK132196A (he)
HU (2) HU221850B1 (he)
IE (2) IE921618A1 (he)
IL (6) IL116109A (he)
MD (1) MD1155C2 (he)
MX (2) MX9202395A (he)
NO (2) NO300593B1 (he)
NZ (2) NZ242817A (he)
OA (1) OA10212A (he)
PL (3) PL176026B1 (he)
RO (1) RO116812B1 (he)
RU (4) RU2223960C2 (he)
SG (1) SG43863A1 (he)
SK (2) SK281954B6 (he)
TW (4) TW366350B (he)
WO (2) WO1992020669A1 (he)
ZA (2) ZA923641B (he)

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5466806A (en) * 1989-02-08 1995-11-14 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
US6350753B1 (en) 1988-04-11 2002-02-26 Biochem Pharma Inc. 2-Substituted-4-substituted-1,3-dioxolanes and use thereof
US6175008B1 (en) 1988-04-11 2001-01-16 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
US6903224B2 (en) 1988-04-11 2005-06-07 Biochem Pharma Inc. Substituted 1,3-oxathiolanes
PT674634E (pt) * 1989-02-08 2003-09-30 Iaf Biochem Int Processos para preparar 1,3-oxatiolanos substituidos com propriedades antivirais
US6642245B1 (en) 1990-02-01 2003-11-04 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US5827727A (en) * 1990-02-01 1998-10-27 Emory University Method of resolution of 1,3-oxathiolane nucleoside enantiomers
US6703396B1 (en) 1990-02-01 2004-03-09 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
US5276151A (en) * 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US5587480A (en) * 1990-11-13 1996-12-24 Biochem Pharma, Inc. Substituted 1,3-oxathiolanes and substituted 1,3-dithiolanes with antiviral properties
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US5925643A (en) * 1990-12-05 1999-07-20 Emory University Enantiomerically pure β-D-dioxolane-nucleosides
US6812233B1 (en) 1991-03-06 2004-11-02 Emory University Therapeutic nucleosides
US5817667A (en) * 1991-04-17 1998-10-06 University Of Georgia Research Foudation Compounds and methods for the treatment of cancer
ZA923641B (en) * 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
US6005107A (en) * 1992-12-23 1999-12-21 Biochem Pharma, Inc. Antiviral compounds
US6444656B1 (en) 1992-12-23 2002-09-03 Biochem Pharma, Inc. Antiviral phosphonate nucleotides
GB9226879D0 (en) * 1992-12-23 1993-02-17 Iaf Biochem Int Anti-viral compounds
GB9226927D0 (en) * 1992-12-24 1993-02-17 Iaf Biochem Int Dideoxy nucleoside analogues
US5627160A (en) * 1993-05-25 1997-05-06 Yale University L-2',3'-dideoxy nucleoside analogs as anti-hepatitis B (HBV) and anti-HIV agents
TW374087B (en) * 1993-05-25 1999-11-11 Univ Yale L-2',3'-dideoxy nucleotide analogs as anti-hepatitis B(HBV) and anti-HIV agents
GB9311709D0 (en) * 1993-06-07 1993-07-21 Iaf Biochem Int Stereoselective synthesis of nucleoside analogues using bicycle intermediate
US20020120130A1 (en) 1993-09-10 2002-08-29 Gilles Gosselin 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents
JPH09504785A (ja) 1993-09-10 1997-05-13 エモリー、ユニバーシティー 抗b型肝炎ウイルス活性を有するヌクレオシド
US5587362A (en) * 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
IL113432A (en) * 1994-04-23 2000-11-21 Glaxo Group Ltd Process for the diastereoselective synthesis of nucleoside analogues
GB9413724D0 (en) * 1994-07-07 1994-08-24 Wellcome Found Therapeutic nucleosides
US6514949B1 (en) 1994-07-11 2003-02-04 University Of Virginia Patent Foundation Method compositions for treating the inflammatory response
US6448235B1 (en) 1994-07-11 2002-09-10 University Of Virginia Patent Foundation Method for treating restenosis with A2A adenosine receptor agonists
IL115156A (en) 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
US6391859B1 (en) 1995-01-27 2002-05-21 Emory University [5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides
US5703058A (en) 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US5808040A (en) * 1995-01-30 1998-09-15 Yale University L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides
US5869461A (en) * 1995-03-16 1999-02-09 Yale University Reducing toxicity of L-nucleosides with D-nucleosides
GB9506644D0 (en) * 1995-03-31 1995-05-24 Wellcome Found Preparation of nucleoside analogues
EP0831852B1 (en) 1995-06-07 2006-11-29 Emory University Nucleosides with anti-hepatitis b virus activity
KR100213932B1 (ko) * 1995-11-02 1999-08-02 김충환 새로운 뉴클레오시드 유도체 및 그 제조방법
GB9600143D0 (en) 1996-01-05 1996-03-06 Wellcome Found Therapeutic compounds
EP0799834A1 (en) * 1996-04-04 1997-10-08 Novartis AG Modified nucleotides
US6005097A (en) * 1996-06-14 1999-12-21 Vion Pharmaceuticals, Inc. Processes for high-yield diastereoselective synthesis of dideoxynucleosides
US5753789A (en) * 1996-07-26 1998-05-19 Yale University Oligonucleotides containing L-nucleosides
US6022876A (en) 1996-11-15 2000-02-08 Yale University L-β-dioxolane uridine analogs and methods for treating and preventing Epstein-Barr virus infections
ATE254131T1 (de) 1997-02-13 2003-11-15 Glaxo Group Ltd Benzimidazolderivate
EP0986375A2 (en) 1997-04-07 2000-03-22 Triangle Pharmaceuticals Inc. Use of mkc-442 in combination with other antiviral agents
WO1998056761A2 (en) 1997-06-10 1998-12-17 Glaxo Group Limited Benzimidazole derivatives
NZ502882A (en) 1997-07-30 2002-02-01 Glaxo Group Ltd Lyxofuranosyl benzimidazoles as antiviral agents
US20030220234A1 (en) * 1998-11-02 2003-11-27 Selvaraj Naicker Deuterated cyclosporine analogs and their use as immunodulating agents
YU44900A (sh) 1998-01-31 2003-01-31 Glaxo Group Limited Derivati 2-(purin-9-il)tetrahidrofuran-3,4-diola
EP1104415B1 (en) 1998-08-12 2004-11-10 Gilead Sciences, Inc. Method of manufacture of 1,3-oxathiolane nucleosides
US6979561B1 (en) 1998-10-09 2005-12-27 Gilead Sciences, Inc. Non-homogeneous systems for the resolution of enantiomeric mixtures
HUP0104827A3 (en) 1998-12-23 2002-08-28 Shire Biochem Inc Laval Antiviral nucleoside analogues
US7635690B2 (en) 1999-01-22 2009-12-22 Emory University HIV-1 mutations selected for by β-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine
US7115584B2 (en) 1999-01-22 2006-10-03 Emory University HIV-1 mutations selected for by β-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine
US7427606B2 (en) * 1999-02-01 2008-09-23 University Of Virginia Patent Foundation Method to reduce inflammatory response in transplanted tissue
US7378400B2 (en) * 1999-02-01 2008-05-27 University Of Virginia Patent Foundation Method to reduce an inflammatory response from arthritis
US6232297B1 (en) * 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
YU25500A (sh) 1999-05-11 2003-08-29 Pfizer Products Inc. Postupak za sintezu analoga nukleozida
US6322771B1 (en) 1999-06-18 2001-11-27 University Of Virginia Patent Foundation Induction of pharmacological stress with adenosine receptor agonists
ATE269081T1 (de) * 1999-09-24 2004-07-15 Shire Biochem Inc Dioxolan nukleosidanalogen zur behandlung und vorbeugung von viralen infektionen
EP1225899A2 (en) 1999-11-04 2002-07-31 Virochem Pharma Inc. Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues
US6436948B1 (en) 2000-03-03 2002-08-20 University Of Georgia Research Foundation Inc. Method for the treatment of psoriasis and genital warts
CA2308559C (en) * 2000-05-16 2005-07-26 Brantford Chemicals Inc. 1,3-oxathiolan-5-ones useful in the production of antiviral nucleoside analogues
KR100927024B1 (ko) * 2001-03-01 2009-11-17 아보트 래버러토리즈 시스-ftc의 다형 및 기타 결정형
CA2351049C (en) 2001-06-18 2007-03-13 Brantford Chemicals Inc. Process for recovery of the desired cis-1,3-oxathiolane nucleosides from their undesired trans-isomers
CA2460911C (en) * 2001-10-01 2011-08-30 University Of Virginia Patent Foundation 2-propynyl adenosine analogs having a2a agonist activity and compositions thereof
EP1714977B1 (en) 2001-10-19 2009-03-11 Isotechnika Inc. Synthesis of cyclosporin analogs
ITMI20012317A1 (it) * 2001-11-06 2003-05-06 Recordati Ind Chimica E Farma Processo diastereoselettivo per la preparazione del'agente antivirale4-amino-1-(2r-idrossimetil-/1,3/ossatiolan-5s-i1)-1h-pirimidin-2-one
CN1620295A (zh) * 2001-12-14 2005-05-25 法玛塞特有限公司 制备用于合成抗病毒核苷的中间体
EP1467990B1 (en) 2002-01-25 2012-03-07 Shire BioChem Inc. Process for producing dioxolane nucleoside analogue precursors
US7365173B2 (en) * 2002-02-04 2008-04-29 American National Red Cross Method for the production of pure virally inactivated butyrylcholinesterase
CA2494183C (en) 2002-08-06 2012-01-03 Kyoichi A. Watanabe Processes for preparing 1,3-dioxolane nucleosides
PL378368A1 (pl) * 2003-01-14 2006-04-03 Gilead Sciences, Inc. Kompozycje i sposoby wykorzystywane w skojarzonej terapii przeciwwirusowej
ITMI20030578A1 (it) * 2003-03-24 2004-09-25 Clariant Lsm Italia Spa Processo ed intermedi per la preparazione di emtricitabina
KR101157468B1 (ko) 2004-02-03 2012-07-06 에모리 유니버시티 1,3-디옥솔란 뉴클레오시드 제조방법
US7442687B2 (en) * 2004-08-02 2008-10-28 The University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having A2A agonist activity
SG155182A1 (en) * 2004-08-02 2009-09-30 Univ Virginia 2-propynyl adenosine analogs with modified 5æ-ribose groups having a2a agonist activity
US7576069B2 (en) * 2004-08-02 2009-08-18 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having A2A agonist activity
US7837651B2 (en) * 2004-08-31 2010-11-23 Ethicon Endo-Surgery, Inc. Infusion pump
US7250416B2 (en) 2005-03-11 2007-07-31 Supergen, Inc. Azacytosine analogs and derivatives
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
WO2007077505A2 (en) * 2005-12-30 2007-07-12 Ranbaxy Laboratories Limited Crystalline l-menthyl (2r, 5s)-5-(4-amino-5-fluoro-2-oxo-2h-pyrimidin-1-yl)[1, 3]oxathiolan-2-carboxylate and process for preparation thereof
WO2007120972A2 (en) * 2006-02-10 2007-10-25 University Of Virginia Patent Foundation Method to treat sickle cell disease
US8188063B2 (en) * 2006-06-19 2012-05-29 University Of Virginia Patent Foundation Use of adenosine A2A modulators to treat spinal cord injury
CA2667891A1 (en) * 2006-10-30 2008-05-08 Lupin Limited An improved process for the manufacture of lamivudine
RU2488591C2 (ru) 2007-09-26 2013-07-27 Маунт Синай Скул Оф Медсин Аналоги азацитидина и их применение
WO2009069011A1 (en) * 2007-11-29 2009-06-04 Ranbaxy Laboratories Limited Process for the preparation of substituted 1,3-oxathiolanes
BRPI0820224A2 (pt) * 2007-11-29 2015-06-16 Ranbaxy Lab Ltd Composto de fórmula iii ou seus estereoisômeros; processo para sua preparação e seu uso; uso de um composto de formula iii(a) ou iii(b) em um processo para a preparação de lamivudina de fórmula i(a) ou um composto de fórmula i(c); processo para preparação de lamivudina de fórmula i(a)
WO2009084033A2 (en) * 2007-12-07 2009-07-09 Matrix Laboratories Limited Process for producing 5-fluoro-1-(2r,5s)-[2-(hydroxymethyl)-1,3-oxathiolan-5-yi]cytosine
US8058259B2 (en) * 2007-12-20 2011-11-15 University Of Virginia Patent Foundation Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
KR101784647B1 (ko) 2008-05-02 2017-10-11 길리애드 사이언시즈, 인코포레이티드 제약 제제의 가공성 향상을 위한 고체 담체 입자의 용도
US20110282046A1 (en) 2009-01-19 2011-11-17 Rama Shankar Process for preparation of cis-nucleoside derivative
KR101738325B1 (ko) 2009-02-06 2017-05-19 길리애드 사이언시즈, 인코포레이티드 조합 요법용 정제
EP2521729A4 (en) * 2010-01-08 2013-07-31 Hetero Research Foundation IMPROVED METHOD FOR NUCLEOSIDES
PT2531027E (pt) 2010-01-27 2015-09-16 Viiv Healthcare Co Combinação terapêutica compreendendo dolutegravir, abacavir e lamivudina
US20120295930A1 (en) * 2010-02-03 2012-11-22 Shankar Rama Novel process for the preparation of cis-nucleoside derivative
CA2792044A1 (en) 2010-03-04 2011-09-09 Ranbaxy Laboratories Limited A process for stereoselective synthesis of 5-fluoro-1-(2r,5s)-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine
EP2377862A1 (en) 2010-03-29 2011-10-19 Esteve Química, S.A. Process for obtaining emtricitabine
WO2011141805A2 (en) 2010-05-14 2011-11-17 Lupin Limited An improved process for the manufacture of lamivudine
CN103221037A (zh) 2010-11-12 2013-07-24 葛兰素惠尔康制造业私人有限公司 新药物组合物
US20130296562A1 (en) 2011-08-05 2013-11-07 Lupin Limited Stereoselective process for preparation of 1,3-oxathiolane nucleosides
CN108635367B (zh) 2011-08-30 2020-08-21 阿斯泰克斯制药公司 地西他滨衍生物制剂
CN103242243B (zh) * 2013-01-08 2015-08-19 北京大学 一种碱基乙酸甘油醚酯分子,其化学合成方法及其在基因治疗领域的应用
CN103288806A (zh) * 2013-07-02 2013-09-11 山东大学 一种曲沙他滨的合成方法
AU2016287585B2 (en) 2015-07-02 2020-12-17 Otsuka Pharmaceutical Co., Ltd. Lyophilized pharmaceutical compositions
CN105037340B (zh) * 2015-07-14 2018-08-10 福建广生堂药业股份有限公司 一种拉米夫定关键中间体手性异构体杂质的制备方法
MX2020001233A (es) 2017-08-03 2020-07-20 Otsuka Pharma Co Ltd Compuesto farmaceutico y metodos de purificacion del mismo.

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1445013A (fr) * 1964-07-09 1966-07-08 Thomae Gmbh Dr K Procédé pour fabriquer des nouveaux acides dioxolano-2-carboxyliques
US4383114A (en) * 1977-02-09 1983-05-10 Regents Of The University Of Minnesota Adenosine deaminase resistant antiviral purine arabinonucleosides
US4231945A (en) * 1978-11-08 1980-11-04 Schering Corporation S-5-(Azidomethyl or aminomethyl)-2-lower-alkoxytetrahydrofurans
US4479942A (en) * 1981-08-10 1984-10-30 Fujisawa Pharmaceutical Co., Ltd. Tetrahydrofurnancarboxylic acid derivatives, processes for preparation thereof and pharmaceutical compositions thereof
US4855304A (en) * 1985-01-10 1989-08-08 Repligen Corporation Dinucleoside pyrophosphates and pyrophosphate homologs as plant antivirals
DK363987A (da) * 1986-08-08 1988-02-09 Hoffmann La Roche Pyrimidinderivater
GB8621268D0 (en) * 1986-09-03 1986-10-08 Univ Strathclyde Separation of substances
US4997818A (en) * 1987-09-21 1991-03-05 The University Hospital Therapeutic method for selectively treating terminal deoxynucleotidyl transferase-positive neoplastic leukemias and lymphomas
SE8704298D0 (sv) * 1987-11-03 1987-11-03 Astra Ab Compounds for use in therapy
US4997926A (en) * 1987-11-18 1991-03-05 Scripps Clinic And Research Foundation Deaminase-stable anti-retroviral 2-halo-2',3'-dideoxy
JPH022349A (ja) * 1988-02-17 1990-01-08 Takeda Chem Ind Ltd ピリミジンアナログ耐性化遺伝子dnaおよびその用途
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
NZ228645A (en) * 1988-04-11 1991-09-25 Iaf Biochem Int 1,3-dioxolane derivatives substituted in the 5th position by a purine or pyrimidine radical; treatment of viral infections
GB8815265D0 (en) * 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
DE3823127A1 (de) * 1988-07-08 1990-01-11 Rheinische Braunkohlenw Ag Vorrichtung und verfahren zur reinigung von abwasser
US4987224A (en) * 1988-08-02 1991-01-22 University Of Georgia Research Foundation, Inc. Method of preparation of 2',3'-dideoxynucleosides
DE3827134A1 (de) * 1988-08-10 1990-03-15 Bayer Ag Substituierte triazolyl- bzw. imidazolyl-hydroxyalkyldioxolane, verfahren zu ihrer herstellung und ihre verwendung als mikrobizide, oxiranyldioxolane, dioxolanylketone, oxiranylketone und (alpha)-halogenketone als zwischenprodukte und verfahren zu deren herstellung
US5075225A (en) * 1989-04-06 1991-12-24 The Texas A&M University System Process for the enzymatic synthesis of nucleosides
NZ233197A (en) * 1989-04-13 1991-11-26 Richard Thomas Walker Aromatically substituted nucleotide derivatives, intermediates therefor and pharmaceutical compositions
NZ234534A (en) * 1989-07-17 1994-12-22 Univ Birmingham Pyrimidine 4'-thionucleoside derivatives and their preparation; intermediates therefor
IE904378A1 (en) * 1989-12-20 1991-07-03 Abbott Lab Analogs of oxetanyl purines and pyrimidines
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
GB9009861D0 (en) * 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
GB9014090D0 (en) * 1990-06-25 1990-08-15 Zaadunie Bv Improvements in or relating to organic compounds
WO1992010496A1 (en) * 1990-12-05 1992-06-25 University Of Georgia Research Foundation, Inc. ENANTIOMERICALLY PURE β-L-(-)-1,3-OXATHIOLANE NUCLEOSIDES
IL100965A (he) * 1991-02-22 1999-12-31 Univ Emory 2 - הידרוקסימתיל - 5 - )5 - פלואורוציטוסין - 1 - איל( - 1, 3 - אוקסאתיולאן, הרזולוציה שלו ותכשירי רוקחות המכילים אותו
WO1992018517A1 (en) * 1991-04-17 1992-10-29 Yale University Method of treating or preventing hepatitis b virus
GB9109506D0 (en) * 1991-05-02 1991-06-26 Wellcome Found Therapeutic nucleosides
ZA923641B (en) * 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides

Also Published As

Publication number Publication date
CZ284975B6 (cs) 1999-04-14
EP0515156A1 (en) 1992-11-25
HUT67726A (en) 1995-04-28
DE69221936D1 (de) 1997-10-09
DE69208144D1 (de) 1996-03-21
GR3018941T3 (en) 1996-05-31
CN1035555C (zh) 1997-08-06
CZ285220B6 (cs) 1999-06-16
IL116109A0 (en) 1996-01-31
CN1229079A (zh) 1999-09-22
KR920021576A (ko) 1992-12-18
TW366349B (en) 1999-08-11
AU1691392A (en) 1992-12-30
PL176026B1 (pl) 1999-03-31
SK281954B6 (sk) 2001-09-11
US5693787A (en) 1997-12-02
SK129393A3 (en) 1994-07-06
FI935150A0 (fi) 1993-11-19
OA10212A (en) 1997-10-07
CN1067245A (zh) 1992-12-23
HK1002431A1 (en) 1998-08-21
KR100242921B1 (ko) 2000-03-15
RO116812B1 (ro) 2001-06-29
US5756706A (en) 1998-05-26
JP3229013B2 (ja) 2001-11-12
IE921618A1 (en) 1992-12-02
CZ222496A3 (cs) 1999-04-14
TWI245046B (en) 2005-12-11
NO921989L (no) 1992-11-23
NZ242817A (en) 1995-03-28
CN1229080A (zh) 1999-09-22
ATE133958T1 (de) 1996-02-15
IE76741B1 (en) 1997-11-05
US5744596A (en) 1998-04-28
EE03044B1 (et) 1997-10-15
EP0515157A1 (en) 1992-11-25
DK0515157T3 (da) 1997-09-29
CN1050603C (zh) 2000-03-22
HU223838B1 (hu) 2005-02-28
KR100232012B1 (ko) 1999-12-01
ES2104832T3 (es) 1997-10-16
CN1067654A (zh) 1993-01-06
SK129493A3 (en) 1994-11-09
JPH05186465A (ja) 1993-07-27
BG61695B1 (bg) 1998-03-31
NO921988D0 (no) 1992-05-20
JPH05186463A (ja) 1993-07-27
DE69221936T2 (de) 1998-01-02
NO921989D0 (no) 1992-05-20
EP0515157B1 (en) 1997-09-03
DK0515156T3 (da) 1996-06-17
MD1155B2 (en) 1999-02-28
RU2223960C2 (ru) 2004-02-20
NO300593B1 (no) 1997-06-23
DE69208144T2 (de) 1996-09-05
HUT67471A (en) 1995-04-28
NZ242818A (en) 1994-04-27
WO1992020669A1 (en) 1992-11-26
EP0515156B1 (en) 1996-02-07
RU2105009C1 (ru) 1998-02-20
ES2084937T3 (es) 1996-05-16
FI935151A (fi) 1993-11-19
JP3704055B2 (ja) 2005-10-05
FI20001900A (fi) 2000-08-29
SG43863A1 (en) 1997-11-14
MX9202395A (es) 1993-02-01
IL101932A0 (en) 1992-12-30
PL170869B1 (pl) 1997-01-31
CZ249393A3 (en) 1994-04-13
NO301010B1 (no) 1997-09-01
US5663320A (en) 1997-09-02
HU221850B1 (hu) 2003-02-28
CA2069063A1 (en) 1992-11-22
IL116176A0 (en) 1996-01-31
SK279438B6 (sk) 1998-11-04
AU1639492A (en) 1992-11-26
CN1097049C (zh) 2002-12-25
FI106377B (fi) 2001-01-31
MX9202404A (es) 1993-08-31
ZA923640B (en) 1993-02-24
CN1038591C (zh) 1998-06-03
AU668086B2 (en) 1996-04-26
MD1155C2 (ro) 1999-10-31
HU9303297D0 (en) 1994-03-28
JP3330972B2 (ja) 2002-10-07
KR0160144B1 (ko) 1998-11-16
BG98311A (bg) 1994-08-30
CN1083450C (zh) 2002-04-24
CN1229078A (zh) 1999-09-22
IE921619A1 (en) 1992-12-02
FI935151A0 (fi) 1993-11-19
ZA923641B (en) 1993-02-24
BG61696B1 (bg) 1998-03-31
FI109025B (fi) 2002-05-15
IL116176A (he) 1998-02-08
IL101931A (he) 1996-12-05
IL101932A (en) 1997-04-15
IL101931A0 (en) 1992-12-30
CA2069024C (en) 1997-09-23
JP2001354667A (ja) 2001-12-25
CA2069063C (en) 1997-07-15
BG98310A (bg) 1994-01-03
TW366350B (en) 1999-08-11
CZ280857B6 (cs) 1996-04-17
GR3024617T3 (en) 1997-12-31
ATE157662T1 (de) 1997-09-15
NO921988L (no) 1992-11-23
WO1992020696A1 (en) 1992-11-26
HK132196A (en) 1996-07-26
AU1639592A (en) 1992-11-26
CA2069024A1 (en) 1992-11-22
FI935150A (fi) 1993-11-19
RU2163909C2 (ru) 2001-03-10
CN1109030C (zh) 2003-05-21
MD950172A (en) 1996-08-30
RU2140925C1 (ru) 1999-11-10
PL168910B1 (pl) 1996-05-31
HU9303296D0 (en) 1994-03-28
GT199800047A (es) 1999-08-26
CZ249293A3 (en) 1994-03-16
TW467907B (en) 2001-12-11
CN1116204A (zh) 1996-02-07
AU1690892A (en) 1992-12-30
US5696254A (en) 1997-12-09
KR920021575A (ko) 1992-12-18
AU655973B2 (en) 1995-01-19

Similar Documents

Publication Publication Date Title
US5744596A (en) Nucleoside analogues and synthetic intermediates
SK135596A3 (en) Process for the diastereoselective synthesis of nucleoside analogues
OA10349A (en) Processes for the diastereoselective synthesis of nucleosides
FI102279B (fi) Välituotteita nukleosidien diastereoselektiivisiin synteesimenetelmiin

Legal Events

Date Code Title Description
FF Patent granted
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees